DK0755919T3 - Substituerede kanelsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som hjerte-kredsløbs-medikament e - Google Patents

Substituerede kanelsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som hjerte-kredsløbs-medikament e

Info

Publication number
DK0755919T3
DK0755919T3 DK96111665T DK96111665T DK0755919T3 DK 0755919 T3 DK0755919 T3 DK 0755919T3 DK 96111665 T DK96111665 T DK 96111665T DK 96111665 T DK96111665 T DK 96111665T DK 0755919 T3 DK0755919 T3 DK 0755919T3
Authority
DK
Denmark
Prior art keywords
preparation
cinnamic acid
cardiovascular drug
substituted cinnamic
guanides
Prior art date
Application number
DK96111665T
Other languages
Danish (da)
English (en)
Inventor
Jan-Robert Schwark
Joachim Brendel
Heinz-Werner Kleemann
Hans Jochen Lang
Andreas Weichert
Udo Albus
Wolfgang Scholz
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0755919T3 publication Critical patent/DK0755919T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK96111665T 1995-07-26 1996-07-19 Substituerede kanelsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som hjerte-kredsløbs-medikament e DK0755919T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19527305A DE19527305A1 (de) 1995-07-26 1995-07-26 Substituierte Zimtsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
DK0755919T3 true DK0755919T3 (da) 2000-04-25

Family

ID=7767840

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96111665T DK0755919T3 (da) 1995-07-26 1996-07-19 Substituerede kanelsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som hjerte-kredsløbs-medikament e

Country Status (29)

Country Link
US (1) US5883133A (zh)
EP (1) EP0755919B1 (zh)
JP (1) JP4177466B2 (zh)
KR (1) KR970006281A (zh)
CN (1) CN1062554C (zh)
AR (1) AR003467A1 (zh)
AT (1) ATE186720T1 (zh)
AU (1) AU704461B2 (zh)
BR (1) BR9603179A (zh)
CA (1) CA2182062C (zh)
CZ (1) CZ289327B6 (zh)
DE (2) DE19527305A1 (zh)
DK (1) DK0755919T3 (zh)
ES (1) ES2140765T3 (zh)
GR (1) GR3032363T3 (zh)
HR (1) HRP960356B1 (zh)
HU (1) HUP9602072A3 (zh)
IL (1) IL118925A (zh)
MX (1) MX9603004A (zh)
MY (1) MY115466A (zh)
NO (1) NO306060B1 (zh)
NZ (1) NZ299052A (zh)
PL (1) PL183439B1 (zh)
RU (1) RU2190601C2 (zh)
SI (1) SI0755919T1 (zh)
SK (1) SK282018B6 (zh)
TR (1) TR199600612A2 (zh)
TW (1) TW536531B (zh)
ZA (1) ZA966313B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19527305A1 (de) * 1995-07-26 1997-01-30 Hoechst Ag Substituierte Zimtsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6110922A (en) 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6878700B1 (en) 1998-12-29 2005-04-12 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
DE10024319A1 (de) * 2000-05-17 2001-11-22 Merck Patent Gmbh Bisacylguanidine
GB0015205D0 (en) * 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
WO2002002539A1 (en) 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
DE10046993A1 (de) 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
CA2468302C (en) * 2001-11-29 2012-08-14 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
DE10258168B4 (de) * 2002-12-12 2005-07-07 Infineon Technologies Ag Integrierter DRAM-Halbleiterspeicher und Verfahren zum Betrieb desselben
KR101153254B1 (ko) 2003-06-26 2012-07-02 바이오트론 리미티드 항바이러스 화합물 및 방법
NZ596107A (en) 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
US20120088737A2 (en) * 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734904A (en) * 1956-02-14 Xcxnhxc-nh
US4544670A (en) 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
CN1036267C (zh) * 1992-02-15 1997-10-29 赫彻斯特股份公司 氨基取代的苯甲酰胍的制备方法
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19527305A1 (de) * 1995-07-26 1997-01-30 Hoechst Ag Substituierte Zimtsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
AU6066896A (en) 1997-01-30
CZ218496A3 (en) 1997-02-12
ATE186720T1 (de) 1999-12-15
AU704461B2 (en) 1999-04-22
RU2190601C2 (ru) 2002-10-10
HRP960356B1 (en) 2001-02-28
ZA966313B (en) 1997-02-11
DE59603659D1 (de) 1999-12-23
AR003467A1 (es) 1998-08-05
NO963108D0 (no) 1996-07-25
PL183439B1 (pl) 2002-06-28
TR199600612A2 (tr) 1997-04-22
HUP9602072A2 (en) 1997-05-28
SK282018B6 (sk) 2001-10-08
GR3032363T3 (en) 2000-04-27
SI0755919T1 (en) 2000-04-30
CA2182062A1 (en) 1997-01-27
DE19527305A1 (de) 1997-01-30
HUP9602072A3 (en) 1997-10-28
CA2182062C (en) 2008-12-02
CN1145899A (zh) 1997-03-26
CZ289327B6 (cs) 2002-01-16
TW536531B (en) 2003-06-11
NZ299052A (en) 1997-10-24
ES2140765T3 (es) 2000-03-01
HRP960356A2 (en) 1998-02-28
BR9603179A (pt) 2002-04-09
KR970006281A (ko) 1997-02-19
JPH0952823A (ja) 1997-02-25
JP4177466B2 (ja) 2008-11-05
SK96596A3 (en) 1997-03-05
NO963108L (no) 1997-01-27
MY115466A (en) 2003-06-30
IL118925A0 (en) 1996-10-31
NO306060B1 (no) 1999-09-13
IL118925A (en) 2001-08-08
EP0755919A3 (de) 1997-04-09
HU9602072D0 (en) 1996-09-30
EP0755919B1 (de) 1999-11-17
MX9603004A (es) 1997-01-31
CN1062554C (zh) 2001-02-28
US5883133A (en) 1999-03-16
PL314279A1 (en) 1997-02-03
EP0755919A2 (de) 1997-01-29

Similar Documents

Publication Publication Date Title
NO20003150D0 (no) FremgangsmÕte for fremstilling av tabletter som oppløses ved tygging
NO20002217L (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
ATE252562T1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
NO993519L (no) Fenofibrat farmasöytisk blanding som har höy biotilgjengelighet og fremgangsmÕte for fremstilling av den
TR199600792A2 (tr) Dihaloazolopirimidinlerin hazirlanmasina yönelik proses.
DK0755919T3 (da) Substituerede kanelsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som hjerte-kredsløbs-medikament e
NO20021398D0 (no) 2'-substituerte 1,1'-bifenyl-2-karbonamider, fremgangsmåte for fremstilling, deres anvendelse som medikament såvel somfarmasöytiske preparater inneholdende disse
DK1453810T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
NO962063D0 (no) Fluorfenylsubstituerte alkenylkarboksylsyre-guanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som medikament inneholdende dem
NO962006D0 (no) Substituerte benzyloksykarbonylguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som legemiddel inneholdende dem
ID28601A (id) Proses penyiapan senyawa-senyawa 1,4-dihidropiridin
DK0830132T3 (da) Farmaceutisk formulering indeholdende tiagabinhydrochlorid samt fremgangsmåden til dets fremstilling
NO904576D0 (no) Aminopyridinylaminofenol og beslektede forbindelser, mellomprodukter, fremgangsmaate for deres fremstilling og anvendelse som medikamenter.
NO975680L (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform
DK0840724T3 (da) Fremgangsmåde til fremstilling af enantiomerisk ren azetidin-2-caboxylsyre
DE60003662D1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DK0815092T3 (da) Fremgangsmåde til fremstilling af 1,2-benzisothiazolin-3-oner
DK1053224T3 (da) Biphenylfulfonylcyanamider, fremgangsmåde til fremstilling deraf og anvendelse deraf som lægemiddel
DK0763535T3 (da) Piperidinylmethyloxazolidin-2-on-derivater, deres fremstilling og deres anvendelse som centralnervesystem-aktive forbindelser
NO20021727D0 (no) Fremgangsmåte for fremstilling av 3,4-metylen-dioksy- mandelisk syre
NO20000995L (no) Optisk rene camptotecin analoger, optisk rent mellomprodukt, fremgangsmÕte for fremstilling av disse
NO962999D0 (no) Fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum, såvel som medikament inneholdende dem
DK0790245T3 (da) Substituerede thiophenylalkenylcarboxylsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som lægemiddel eller diagnostikum samt lægemiddel med indhold deraf
DK0915076T3 (da) Fremgangsmåde til fremstilling af trans-(R,R)-actinol
DK1413575T3 (da) Fremgangsmåde til fremstilling af derivater af (1,5-diaryl)pyrazol-3-ylpropansyre